Health care stocks were mixed premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was down a slight 0.2% and the iShares Biotechnology ETF (IBB) was recently inactive.
Humana (HUM) shares rose nearly 3% after the company reported an increase in Q4 revenue and issued a 2025 revenue outlook above analysts' expectations.
Biohaven (BHVN) shares advanced by over 7% after the company said the Food and Drug Administration accepted for priority review its new drug application for troriluzole to treat adult patients with spinocerebellar ataxia.
Royalty Pharma (RPRX) shares were down more than 0.4% after the company reported lower Q4 net income and revenue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.